Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lawrence Blonde

Showing results (61-70 of 144) with videos related to

Pageof 15
Sort By:
Advances in Therapy|November 12, 2020
Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United StatesLawrence Blonde, Charmi Patel, Bingcao Wu, et al.
The American Journal of Managed Care|March 4, 2015
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trialsRobert A Bailey, Ujjwala Vijapurkar, Gary E Meininger, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2013
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendationsAlan J Garber, Lawrence Blonde, Zachary T Bloomgarden, et al.
Ochsner Journal|May 24, 2011
Quality of care indicators, health behaviors, and physical functioning in adults with diabetesMarie Krousel-Wood, David M Radosevich, Clese Erikson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 14, 2020
Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-LLawrence Blonde, Lori Berard, Aramesh Saremi, et al.
Journal of the American Heart Association|January 15, 2013
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjectsJ Michael Gaziano, Anthony H Cincotta, Aaron Vinik, et al.
Current Medical Research and Opinion|September 17, 2015
Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trialsLawrence Blonde, Vincent Woo, Chantal Mathieu, et al.
Current Medical Research and Opinion|May 4, 2004
Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort studyLawrence Blonde, George E Dailey, Serge A Jabbour, et al.
JMIR Diabetes|June 10, 2021
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort StudyRichard Milani, Pavan Chava, Jonathan Wilt, et al.
Diabetes, Obesity & Metabolism|June 16, 2020
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trialLuigi Meneghini, Lawrence Blonde, Jasvinder Gill, et al.
Pageof 15

Showing results (61-70 of 144) with videos related to

Sort By:
Pageof 15
Advances in Therapy|November 12, 2020
Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United StatesLawrence Blonde, Charmi Patel, Bingcao Wu, et al.
The American Journal of Managed Care|March 4, 2015
Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trialsRobert A Bailey, Ujjwala Vijapurkar, Gary E Meininger, et al.
Endocrine Practice : Official Journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists|January 23, 2013
The role of bromocriptine-QR in the management of type 2 diabetes expert panel recommendationsAlan J Garber, Lawrence Blonde, Zachary T Bloomgarden, et al.
Ochsner Journal|May 24, 2011
Quality of care indicators, health behaviors, and physical functioning in adults with diabetesMarie Krousel-Wood, David M Radosevich, Clese Erikson, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|March 14, 2020
Fixed-Ratio Combination of Insulin and GLP-1 RA in Patients with Longstanding Type 2 Diabetes: A Subanalysis of LixiLan-LLawrence Blonde, Lori Berard, Aramesh Saremi, et al.
Journal of the American Heart Association|January 15, 2013
Effect of bromocriptine-QR (a quick-release formulation of bromocriptine mesylate) on major adverse cardiovascular events in type 2 diabetes subjectsJ Michael Gaziano, Anthony H Cincotta, Aaron Vinik, et al.
Current Medical Research and Opinion|September 17, 2015
Achievement of treatment goals with canagliflozin in patients with type 2 diabetes mellitus: a pooled analysis of randomized controlled trialsLawrence Blonde, Vincent Woo, Chantal Mathieu, et al.
Current Medical Research and Opinion|May 4, 2004
Gastrointestinal tolerability of extended-release metformin tablets compared to immediate-release metformin tablets: results of a retrospective cohort studyLawrence Blonde, George E Dailey, Serge A Jabbour, et al.
JMIR Diabetes|June 10, 2021
Improving Management of Type 2 Diabetes Using Home-Based Telemonitoring: Cohort StudyRichard Milani, Pavan Chava, Jonathan Wilt, et al.
Diabetes, Obesity & Metabolism|June 16, 2020
Insulin glargine 300 U/mL versus first-generation basal insulin analogues in insulin-naïve adults with type 2 diabetes: 12-month outcomes of ACHIEVE Control, a prospective, randomized, pragmatic real-life clinical trialLuigi Meneghini, Lawrence Blonde, Jasvinder Gill, et al.
Pageof 15